Retatrutide vs Semaglutide for weight loss
Short answer: For weight loss, more users report improvement with Retatrutide — 91% of 222 reports, versus 84% of 129 for Semaglutide.
Retatrutide has 22 meta-analyses and 6 randomized trials on PubMed; Semaglutide has 421 and 307.
Based on 446 reports about Retatrutide and 314 about Semaglutide. Not medical advice.
| Retatrutide Peptide | Semaglutide Medication | |
|---|---|---|
| User score | 71 | 64 |
| Verdict | Mostly positive | Mostly positive |
| Positive of reports that state an outcome | 76% | 64% |
| Reports | 446 | 314 |
| Research | BResearch: Moderate | AResearch: Strong |
| Meta-analyses / RCTs | 22 / 6 | 421 / 307 |
| Mainly used for | ||
| Weight loss % reporting improvement | 91% (222) | 84% (129) |
| Appetite % reporting improvement | 73% (84) | 83% (64) |
| Focus % reporting improvement | 83% (6) | 60% (5) |
| Energy % reporting improvement | 69% (75) | 39% (23) |
| Sleep % reporting improvement | 31% (26) | 50% (4) |
| Anxiety % reporting improvement | 40% (5) | — |
| Mood % reporting improvement | 66% (32) | 27% (11) |
| Performance % reporting improvement | 82% (33) | 83% (6) |
| Recovery % reporting improvement | 100% (8) | 100% (2) |
| Pain & inflammation % reporting improvement | 78% (9) | 80% (5) |
| Digestion % reporting improvement | 46% (13) | 43% (7) |
| Libido % reporting improvement | 25% (12) | 0% (3) |
| Hormones % reporting improvement | 100% (13) | 100% (2) |
| Blood sugar % reporting improvement | 75% (4) | 88% (8) |
| Heart & lipids % reporting improvement | 37% (19) | 100% (3) |
| Skin & hair % reporting improvement | — | 33% (3) |
| Common side effects | nausea, fatigue, stomach issues, insomnia | nausea, fatigue, stomach issues, constipation |
| Typical dose reported | Not listed | 2.4 mg / once weekly |
This systematic review identifies the state and mechanism of action of emerging pharmacotherapies undergoing or having completed phase 2 and phase 3 clinical trials. The information provided herein furthers the understanding of obesity management, implying direct clinical implications and stimulating research initiatives.
Pharmacol Rev, 2025 ↗“Drastically reduced appetite: At 5mg, I experienced near-total suppression of hunger and cravings. Steady, effortless fat loss: I didn't have to track macros obsessively or do extreme cardio.”
This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.
Pharmacol Res, 2021 ↗“I've lost 35lbs since then and now I'm in the Healthy range on BMI. My IBSD has virtually disappeared.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate